- Home
- BXP vs ABVX Comparison
BXP vs ABVX Comparison
Compare BXP & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BXP | ABVX |
|---|---|---|
| Founded | 1970 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 9.2B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | BXP | ABVX |
|---|---|---|
| Price | $64.03 | $113.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 11 |
| Target Price | $76.95 | ★ $130.09 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 01-27-2026 | 08-11-2025 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | ★ 1833.33 | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $3,482,279,000.00 | $6,231,374.00 |
| Revenue This Year | $2.98 | $6.80 |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | $37.48 | ★ N/A |
| Revenue Growth | ★ 3.02 | N/A |
| 52 Week Low | $54.22 | $4.77 |
| 52 Week High | $79.33 | $148.83 |
Technical Indicators
Market Signals| Indicator | BXP | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 34.83 | 42.45 |
| Support Level | $65.47 | $113.64 |
| Resistance Level | $65.93 | $125.00 |
| Average True Range (ATR) | 1.71 | 7.79 |
| MACD | -0.15 | -0.84 |
| Stochastic Oscillator | 23.97 | 23.04 |
Price Performance
Historical ComparisonAbout BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.